IDiyas

For the Inventor, By the Inventor

Ann Arbor, MI, United States of America

Elizabeth Ann Lunney

USPTO Granted Patents = 18

Average Co-Inventor Count = 5.3

ph-index = 7

Forward Citations = 223(Granted Patents)


Company Filing History:

goldMedal16 out of 2,538 
 
Warner-lambert Company
 patents
silverMedal1 out of 22 
 
Warner Lambert LLC
 patents
bronzeMedal1 out of 174 
 
Agouron Pharmaceuticals, Inc.
 patents

Years Active: 1978-2005

Loading Chart...
18 patents (USPTO):Explore Patents
1. 6927217 - HIV protease inhibitors (2005-08-09),
2. 6852711 - HIV protease inhibitors (2005-02-08),
3. 6528510 - HIV protease inhibitors (2003-03-04),
4. 6512006 - HIV protease inhibitors (2003-01-28),
5. 6083981 - Sulfonamide substituted aspartic acid interleukin-1.beta. converting (2000-07-04),
6. 6046355 - Dihydropyrones with improved antiviral activity (2000-04-04),
7. 6005103 - Pyrone derivatives as protease inhibitors and antiviral agents (1999-12-21),
8. 5936128 - 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents (1999-08-10),
9. 5922697 - Compounds, compositions and methods for inhibiting the binding of (1999-07-13),
10. 5840751 - 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents (1998-11-24),
11. 5834506 - Dihydropyrones with improved antiviral activity (1998-11-10),
12. 5808062 - Pyrone derivatives as protease inhibitors and antiviral agents (1998-09-15),
13. 5789440 - 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents (1998-08-04),
14. 5510375 - Coumarin derivatives as protease inhibitors and antiviral agents (1996-04-23),
15. 4804743 - Proline-containing renin inhibitors (1989-02-14),

Title: The Innovative Contributions of Elizabeth Ann Lunney

Introduction

Elizabeth Ann Lunney is a prominent inventor based in Ann Arbor, MI (US). She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of HIV protease inhibitors. With a total of 18 patents to her name, Lunney's work has been instrumental in advancing therapies for viral infections and diseases, including AIDS.

Latest Patents

Lunney's latest patents focus on novel dihydropyrones that inhibit the HIV aspartyl protease, effectively blocking HIV infectivity. The first patent describes dihydropyrones of Formula I, wherein X is NH or NR, which are useful in developing therapies for the treatment of viral infections. The second patent highlights dihydropyrones with tethered heterocycles that possess improved pharmacologic properties, also aimed at inhibiting HIV infectivity. Additionally, these patents include methods of synthesis for the dihydropyrones and intermediates that are essential for preparing the final compounds.

Career Highlights

Throughout her career, Lunney has worked with notable companies such as Warner-Lambert Company and Warner Lambert LLC. Her innovative research has led to advancements in the pharmaceutical industry, particularly in the fight against HIV/AIDS.

Collaborations

Lunney has collaborated with esteemed colleagues, including Bradley Dean Tait and Edmund Lee Ellsworth, contributing to her success in the field of invention and innovation.

Conclusion

Elizabeth Ann Lunney's contributions to the development of HIV protease inhibitors exemplify her dedication to advancing medical science. Her innovative work continues to impact the treatment of viral infections and diseases, making her a significant figure in the realm of pharmaceutical inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…